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Foreword
The purpose of this Alert is to increase awareness among health care workers and their em­
ployers about the health risks posed by working with hazardous drugs and to provide them 
with measures for protecting their health. Health care workers who prepare or administer 
hazardous drugs or who work in areas where these drugs are used may be exposed to these 
agents in the air or on work surfaces, contaminated clothing, medical equipment, patient 
excreta, and other surfaces. Studies have associated workplace exposures to hazardous 
drugs with health effects such as skin rashes and adverse reproductive outcomes (including 
infertility, spontaneous abortions, and congenital malformations) and possibly leukemia and 
other cancers. The health risk is influenced by the extent of the exposure and the potency 
and toxicity of the hazardous drug. To provide workers with the greatest protection, employers 
should (1) implement necessary administrative and engineering controls and (2) assure that 
workers use sound procedures for handling hazardous drugs and proper protective equip­
ment. The Alert contains a list of drugs that should be handled as hazardous drugs.
This Alert applies to all workers who handle hazardous drugs (for example, pharmacy and 
nursing personnel, physicians, operating room personnel, environmental services workers, 
workers in research laboratories, veterinary care workers, and shipping and receiving person­
nel). Although not all workers in these categories handle hazardous drugs, the number of 
exposed workers exceeds 5.5 million. The Alert does not apply to workers in the drug manu­
facturing sector.
The production, distribution, and application of pharmaceutical medications are part of a 
rapidly growing field of patient therapy. New areas of pharmaceutical development will bring 
fundamental changes to methods for treating and preventing diseases. Both traditional med­
ications and bioengineered drugs can be hazardous to health care workers who must handle 
them. This NIOSH Alert will help make workers and employers more aware of these hazards 
and provide the tools for preventing exposures.
Director
National Institute for Occupational 
Safety and Health 
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Preventing Occupational Exposures to 
Antineoplastic and Other Hazardous 
Drugs in Health Care Settings
Warning!
Working with or near hazardous drugs in health care settings 
may cause skin rashes, infertility, miscarriage, birth defects, 
and possibly leukemia or other cancers.
The National Institute for Occupational 
Safety and Health (NIOSH) requests as­
sistance in preventing occupational ex­
posures to antineoplastic drugs (drugs 
used to treat cancer) and other hazard­
ous drugs in health care settings. Health 
care workers who work with or near haz­
ardous drugs may suffer from skin rash­
es, infertility, miscarriage, birth defects, 
and possibly leukemia or other cancers.
Workers may be exposed to hazardous 
drugs in the air or on work surfaces, 
clothing, medical equipment, and pa­
tient urine or feces. The term hazardous 
drugs, as it is used in this Alert, includes 
drugs that are known or suspected to 
cause adverse health effects from ex­
posures in the workplace. They include 
drugs used for cancer chemotherapy, 
antiviral drugs, hormones, some bio­
engineered drugs, and other miscella­
neous drugs. The health risk depends 
on how much exposure a worker has to 
these drugs and how toxic they are. Ex­
posure risks can be greatly reduced by
(1) making sure that engineering con­
trols such as a ventilated cabinet are 
used and (2) using proper procedures 
and protective equipment for handling 
hazardous drugs.
This Alert warns health care workers 
about the risks of working with haz­
ardous drugs and recommends meth­
ods and equipment for protecting their 
health. The Alert addresses workers in 
health care settings, veterinary medi­
cine, research laboratories, retail phar­
macies, and home health care agen­
cies; it does not address workers in the 
drug manufacturing sector. Included in 
the Alert are five case reports of work­
ers who suffered adverse health effects 
after being exposed to antineoplastic 
drugs.
NIOSH requests that employers, editors 
of trade journals, safety and health of­
ficials, and unions bring the recommen­
dations in this Alert to the attention of 
all workers who are at risk.
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BACKGROUND
Drugs have a successful history of use in 
treating illnesses and injuries, and they 
are responsible for many of our medical 
advances over the past century. However, 
virtually all drugs have side effects associ­
ated with their use by patients. Thus, both 
patients and workers who handle them are 
at risk of suffering these effects. In addi­
tion, it is known that exposures to even very 
small concentrations of certain drugs may 
be hazardous for workers who handle them 
or work near them.
The term hazardous drugs was first used by 
the American Society of Hospital Pharma­
cists (ASHP) [ASHP 1990] and is currently 
used by the Occupational Safety and Health 
Administration (OSHA) [OSHA 1995, 1999]. 
Drugs are classified as hazardous if studies 
in animals or humans indicate that expo­
sures to them have a potential for causing 
cancer, developmental or reproductive tox­
icity, or harm to organs. Many hazardous 
drugs are used to treat illnesses such as 
cancer or HIV infection [Galassi et al. 1996; 
Mclnnes and Schilsky 1996; Erlichman and 
Moore 1996]. See Appendix A for examples 
of hazardous drugs and a full discussion of 
criteria used to define and classify them as 
hazardous.
Although the potential therapeutic benefits 
of hazardous drugs outweigh the risks of side 
effects for ill patients, exposed health care 
workers risk these same side effects with no 
therapeutic benefit. Occupational exposures 
to hazardous drugs can lead to (1) acute 
effects such as skin rashes [McDiarmid and 
Egan 1988; Valanis et al. 1993a,b; Krstev 
et al. 2003]; (2) chronic effects, including 
adverse reproductive events [Selevan et al. 
1985; Hemminki et al. 1985; Stucker et al.
1990; Valanis et al. 1997, 1999; Peelen et 
al. 1999]; and (3) possibly cancer [Skov et 
al. 1992].
Guidelines have been established for han­
dling hazardous drugs, but adherence to 
these guidelines has been reported to be 
sporadic [Valanis et al. 1991, 1992; Ma­
hon et al. 1994; Nieweg et al. 1994]. In 
addition, measurable concentrations of 
some hazardous drugs have been docu­
mented in the urine of health care workers 
who prepared or administered them—even 
after safety precautions had been employed 
[Ensslin et al. 1994, 1997; Sessink et al. 
1992b, 1994a,b, 1997; Minoia et al. 1998; 
Wick et al. 2003]. Environmental studies of 
patient-care areas have documented mea­
surable concentrations of drug contamina­
tion, even in facilities thought to be following 
recommended handling guidelines [Minoia 
et al. 1998; Connor et al. 1999; Pethran et 
al. 2003].
The numbers and types of work environments 
containing antineoplastic drugs are expand­
ing as these agents are used increasingly for 
nonmalignant rheumatologic and immuno­
logic diseases [Baker et al. 1987; Moody et 
al. 1987; Chabner et al. 1996; Abel 2000] 
and for chemotherapy in veterinary medi­
cine [Rosenthal 1996; Takada 2003]. This 
Alert summarizes the health effects asso­
ciated with occupational exposure to these 
agents and provides recommendations for 
safe handling.
POTENTIAL FOR WORKER 
EXPOSURE
Workers may be exposed to a drug through­
out its life cycle—from manufacture to
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transport and distribution, to use in health 
care or home care settings, to waste dis­
posal. The number of workers who may be 
exposed to hazardous drugs exceeds 5.5 
million [U.S. Census Bureau 1997; BLS 
1998, 1999; NCHS 1996]. These workers 
include shipping and receiving personnel, 
pharmacists and pharmacy technicians, 
nursing personnel, physicians, operating 
room personnel, environmental services 
personnel, and workers in veterinary prac­
tices where hazardous drugs are used. This 
Alert addresses workers in health care set­
tings, veterinary medicine, research labora­
tories, retail pharmacies, and home health 
care agencies; it does not address workers 
in the drug manufacturing sector.
CONDITIONS FOR EXPOSURE
Both clinical and nonclinical workers may be 
exposed to hazardous drugs when they cre­
ate aerosols, generate dust, clean up spills, 
or touch contaminated surfaces during the 
preparation, administration, or disposal of 
hazardous drugs. The following list of activi­
ties may result in exposures through inhala­
tion, skin contact, ingestion, or injection:
■ Reconstituting powdered or lyophilized 
drugs and further diluting either the re­
constituted powder or concentrated liq­
uid forms of hazardous drugs [Fransman 
et al. 2004]
■ Expelling air from syringes filled with haz­
ardous drugs
■ Administering hazardous drugs by intra­
muscular, subcutaneous, or intravenous 
(IV) routes
■ Counting out individual, uncoated oral 
doses and tablets from multidose bot­
tles
■ Unit-dosing uncoated tablets in a unit­
dose machine
■ Crushing tablets to make oral liquid 
doses [Dorr and Alberts 1992; Shahsa- 
varani et al. 1993; Harrison and Schultz
2000]
■ Compounding potent powders into cus- 
tom-dosage capsules
■ Contacting measurable concentrations of 
drugs present on drug vial exteriors, work 
surfaces, floors, and final drug products 
(bottles, bags, cassettes, and syringes) 
[McDevitt et al. 1993; Sessink et al. 
1992a,b, 1994b; Minoia et al. 1998; 
Connor et al. 1999, 2002; Schmaus et 
al. 2002]
■ Generating aerosols during the adminis­
tration of drugs, either by direct IV push 
or by IV infusion
■ Priming the IV set with a drug-contain­
ing solution at the patient bedside (this 
procedure should be done in the phar­
macy)
■ Handling body fluids or body-fluid-con­
taminated clothing, dressings, linens, 
and other materials [Cass and Musgrave 
1992; Kromhout et al. 2000]
■ Handling contaminated wastes gener­
ated at any step of the preparation or 
administration process
■ Performing certain specialized proce­
dures (such as intraoperative intraperi­
toneal chemotherapy) in the operating 
room [White et al. 1996; Stuart et al.
2002]
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■ Handling unused hazardous drugs or 
hazardous-drug-contaminated waste
■ Decontaminating and cleaning drug 
preparation or clinical areas
■ Transporting infectious, chemical, or 
hazardous waste containers
■ Removing and disposing of personal pro­
tective equipment (PPE) after handling 
hazardous drugs or waste
EXPOSURE ROUTES
Exposures to hazardous drugs may occur 
through inhalation, skin contact, skin ab­
sorption, ingestion, or injection. Inhalation 
and skin contact/absorption are the most 
likely routes of exposure, but unintentional 
ingestion from hand to mouth contact and 
unintentional injection through a needle- 
stick or sharps injury are also possible [Du­
vall and Baumann 1980; Dorr 1983; Black 
and Presson 1997; Schreiber et al. 2003].
A number of studies have attempted to 
measure airborne concentrations of an­
tineoplastic drugs in health care settings 
[Kleinberg and Quinn 1981; Neal et al. 
1983; McDiarmid et al. 1986; Pyy et al. 
1988; McDevitt et al. 1993; Sessink et al. 
1992a; Nygren and Lundgren 1997; Stuart 
et al. 2002; Kiffmeyer et al. 2002; Larson et 
al. 2003]. In most cases, the percentage of 
air samples containing measurable airborne 
concentrations of hazardous drugs was low, 
and the actual concentrations of the drugs, 
when present, were quite low. These results 
may be attributed to the inefficiency of sam­
pling and analytical techniques used in the 
past [Larson et al. 2003]. Both particulate 
and gaseous phases of one antineoplastic
drug, cyclophosphamide, have been report­
ed in two studies [Kiffmeyer et al. 2002; 
Larson et al. 2003].
Since the early 1990s, 14 studies have 
examined environmental contamination of 
areas where hazardous drugs are prepared 
and administered at health care facilities in 
the United States and several other coun­
tries [Sessink et al. 1992a; Sessink et al. 
1992b; McDevitt et al. 1993; Pethran et 
al. 1998; Minoia et al. 1998; Rubino et al. 
1999; Sessink and Bos 1999; Connor et al. 
1999; Micoli et al. 2001; Vandenbroucke et 
al. 2001; Connor et al. 2002; Kiffmeyer et 
al. 2002; Schmaus et al. 2002; Wick et al.
2003]. Using wipe samples, most investi­
gators measured detectable concentrations 
of one to five hazardous drugs in various 
locations such as biological safety cabinet 
(BSC) surfaces, floors, counter tops, stor­
age areas, tables and chairs in patient treat­
ment areas, and locations adjacent to drug- 
handling areas. All of the studies reported 
some level of contamination with at least 
one drug, and several reported contamina­
tion with all the drugs for which assays were 
performed. Such widespread contamination 
of work surfaces makes the potential for 
skin contact highly probable in both phar­
macy and patient areas.
EVIDENCE FOR WORKER 
EXPOSURE
Evidence indicates that workers are be­
ing exposed to hazardous drugs and are 
experiencing serious health effects despite 
current work practice guidelines. Protection 
from hazardous drug exposures depends on 
safety programs established by employers
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and followed by workers. Factors that affect 
worker exposures include the following:
■ Drug handling circumstances (prepara­
tion, administration, or disposal)
■ Amount of drug prepared
■ Frequency and duration of drug handling
■ Potential for absorption
■ Use of ventilated cabinets*
■ PPE
■ Work practices
The likelihood that a worker will experience 
adverse effects from hazardous drugs increas­
es with the amount and frequency of exposure 
and the lack of proper work practices.
Worker exposures have been assessed by 
studies of biological markers of exposure. 
No single biological marker has been found 
to be a good indicator of exposure to haz­
ardous drugs or a good predictor of adverse 
health effects [Baker and Connor 1996]. 
Sessink and Bos [1999] noted that 11 of 
12 studies reported cyclophosphamide in 
the urine of health care workers tested, in­
dicating continued exposure despite safety 
precautions.
Harrison [2001] reported that six differ­
ent drugs (cyclophosphamide, methotrex­
ate, ifosfamide, epirubicin and cisplatin/ 
carboplatin) were detected in the urine of 
health care workers by 13 of 20 inves­
tigations. Two recent studies have docu­
mented antineoplastic drugs in the urine
*A ventilated cabinet is a type of engineering control designed 
to protect workers. Examples include BSCs and isolators 
designed to prevent hazardous drugs inside the cabinet 
from escaping into the work environment. See the Glossary 
in Appendix B for additional descriptions of engineering 
controls.
of pharmacy and nursing personnel [Peth- 
ran et al. 2003; Wick et al. 2003]. Pethran 
and coworkers collected urine samples in
14 German hospitals over a 3-year period. 
Cyclophosphamide, ifosfamide, doxorubi­
cin, and epirubicin (but not daunorubicin or 
idarubicin) and platinum (from cisplatin or 
carboplatin) were identified in urine samples 
from many of the study participants. A U.S. 
investigation demonstrated that use of a 
closed-system device for 6 months reduced 
both the concentration of cyclophospha­
mide or ifosfamide in the urine of exposed 
health care workers and the percentage of 
samples containing these drugs [Wick et 
al. 2003]. Hazardous drugs have also been 
documented in the urine of health care 
workers who did not handle hazardous drugs 
but were potentially exposed through fugi­
tive aerosols or secondary contamination of 
work surfaces, clothing, or drug containers 
[Sessink et al. 1994b; Mader et al. 1996; 
Pethran et al. 2003].
EVIDENCE FOR HEALTH EFFECTS 
IN WORKERS
By the 1970s, the carcinogenicity of several 
antineoplastic drugs in animals was well 
established [Shimkin et al. 1966; Weis­
berger 1975; Schmahl and Habs 1978]. 
Likewise, a number of researchers during 
this period linked the therapeutic use of 
alkylating agents in humans to subsequent 
leukemias and other cancers [Harris 1975, 
1976; IARC 1979]. Many health care pro­
fessionals began to question the safety of 
occupational exposure to these agents [Ng 
and Jaffe 1970; Donner 1978; Johansson 
1979].
Hazardous Drugs in Health Care Settings 5
Mutagenicity Cancer
A number of studies indicate that antineo­
plastic drugs may cause increased genotoxic 
effects in pharmacists and nurses exposed in 
the workplace [Falck et al. 1979; Anderson 
et al 1982; Nguyen et al. 1982; Rogers and 
Emmett 1987; Oestricher et al. 1990; Fuchs 
et al. 1995; Undeger et al. 1999; Norppa et 
al. 1980; Nikula et al. 1984; McDiarmid et 
al. 1992; Sessink et al. 1994a; Burgaz et al. 
1988]. Several studies that have not linked 
genotoxic effects with worker exposures may 
be explained by technical confounders and 
a lack of accurate blood and urine sampling 
in exposed workers [Sorsa et al. 1985; Mc­
Diarmid et al. 1992]. When all the data are 
considered, the weight of evidence associ­
ates hazardous drug exposures at work with 
increased genotoxicity [Sorsa and Anderson 
1996; Baker and Connor 1996; Bos and 
Sessink 1997; Hewitt 1997; Sessink and 
Bos 1999; Harrison and Schulz 2001].
Developmental and Reproductive 
Effects
A recent review of 14 studies described 
an association between exposure to anti­
neoplastic drugs and adverse reproductive 
effects, and 9 studies showed some posi­
tive association [Harrison 2001]. The major 
reproductive effects found in these stud­
ies were increased fetal loss [Selevan et 
al. 1985; Stucker et al. 1990], congenital 
malformations depending on the length of 
exposure [Hemminki et al. 1985], low birth 
weight and congenital abnormalities [Peel- 
en et al. 1999], and infertility [Valanis et al. 
1999].
Several reports have addressed the rela­
tionship of cancer occurrence to health care 
workers’ exposures to antineoplastic drugs. 
A significantly increased risk of leukemia 
has been reported among oncology nurses 
identified in the Danish cancer registry for 
the period 1943-1987 [Skov et al. 1992]. 
The same group [Skov et al. 1990] found 
an increased, but not significant, risk of leu­
kemia in physicians employed for at least
6 months in a department where patients 
were treated with antineoplastic drugs.
CURRENT STANDARDS AND 
RECOMMENDATIONS
Currently, no NIOSH recommended exposure 
limits (RELs), OSHA permissible exposure 
limits (PELs), or American Conference of 
Governmental Industrial Hygienists (ACGIH) 
threshold limit values (TLVs®) have been 
established for hazardous drugs in general. 
An OSHA PEL and an ACGIH TLV have been 
established for soluble platinum salts [29 
CFRf 1910.1000; ACGIH 2003]. However, 
these standards are based on sensitization 
and not on the potential to cause cancer. A 
PEL, an REL, and a TLV have also been es­
tablished for inorganic arsenic compounds, 
which include the antineoplastic drug ar­
senic trioxide [29 CFR 1910.1018; NIOSH 
2004; ACGIH 2003]. A workplace environ­
mental exposure level (WEEL) has been 
established for some antibiotics, including 
chloramphenicol (AIHA 2002). Some phar­
maceutical manufacturers develop risk- 
based occupational exposure limits (OELs) 
to be used in their own manufacturing set­
tings, and this information may be available
fCode of Federal Regulations. See CFR in references.
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on material safety data sheets (MSDSs) or 
from the manufacturer [Sargent and Kirk 
1988; Naumann and Sargent 1997; Sar­
gent et al. 2002].
U.S. Environmental Protection Agency (EPA) 
regulations under the Resource Conserva­
tion and Recovery Act (RCRA) [42 USC 
6901-6992] apply to the management of 
hazardous wastes, which include nine anti­
neoplastic drugs [40 CFR 260-279].
OSHA
OSHA originally published guidelines for anti­
neoplastic drugs in 1986 [OSHA 1986]. Cur­
rent OSHA standards and guidelines that ad­
dress hazardous drugs include the following:
■ Hazard communication standard [29 CFR 
1910.1200]
■ Occupational exposure to hazardous che­
micals in laboratories standard [29 CFR 
1910.1450]
■ OSHA Technical Manual; Section VI, 
Chapter 2: Controlling Occupational Expo­
sure to Hazardous Drugs [OSHA 1999]. 
Main elements of these 1999 OSHA 
guidelines include the following:
- Categorization of drugs as hazardous
- Hazardous drugs as occupational risks
— Work area
- Prevention of employee exposure
- Medical surveillance
- Hazard communication
- Training and information dissemina­
tion
- Recordkeeping
*United States Code. See USC in references.
EPA
EPA/RCRA regulations require that haz­
ardous waste be managed by following a 
strict set of regulatory requirements [40 
CFR 260-279]. The RCRA list of hazard­
ous wastes was developed in 1976 and 
includes only about 30 pharmaceuticals, 9 
of which are antineoplastic drugs. Recent 
evidence indicates that a number of drug 
formulations exhibit hazardous waste char­
acteristics [Smith 2002]. OSHA [1999] and 
ASHP [1990] recommend that hazardous 
drug waste be disposed of in a manner simi­
lar to that required for RCRA-listed hazard­
ous waste. Hazardous drug waste includes 
partially filled vials, undispensed products, 
unused IVs, needles and syringes, gloves, 
gowns, underpads, contaminated materials 
from spill cleanups, and containers such as 
IV bags or drug vials that contain more than 
trace amounts of hazardous drugs and are 
not contaminated by blood or other poten­
tially infectious waste. Published EPA guide­
lines are as follows:
■ U.S. Environmental Protection Agency 
(EPA). Managing Hazardous Waste: A 
Guide for Small Businesses [EPA 2001].
■ U.S. Environmental Protection Agency 
(EPA). RCRA Hazardous Waste Regula­
tions [40 CFR Parts 260-279].
Additional Guidelines
Additional guidelines that address hazard­
ous drugs or the equipment in which they 
are manipulated include the following:
■ Centers for Disease Control (CDC) and 
National Institutes of Health (NIH). Pri­
mary Containment for Biohazards [CDC/ 
NIH 2000]. Provides guidance on the 
selection, installation, testing, and use 
of BSCs.
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■ NIH. Recommendations for the Safe 
Handling of Cytotoxic Drugs [NIH 2002]. 
Includes recommendations for the safe 
preparation and administration of cyto­
toxic drugs.
■ ASHP ASHP Technical Assistance Bulle­
tin on Handling Cytotoxic and Hazardous 
Drugs [ASHP 1990]. An informed dis­
cussion of the dangers and safe handling 
procedures for hazardous drugs.
■ Oncology Nursing Society. Chemotherapy 
and Biotherapy Guidelines and Recom­
mendations for Practice [Brown et al.
2001]. Provides complete guidelines for 
the administration of antineoplastic drugs, 
including safe handling guidelines.
■ Oncology Nursing Society. Safe Handling 
of Hazardous Drugs [Polovich 2003]. 
Includes proper handling guidelines for 
hazardous drugs.
■ United States Pharmacopeia. Chapter 
<797> Pharmaceutical Compounding- 
Sterile Preparations [USP 2004]. Details 
the procedures and requirements for 
compounding sterile preparations and 
sets standards applicable to all settings 
in which sterile preparations are com­
pounded.
■ National Sanitation Foundation (NSF) 
and American National Standards Insti­
tute (ANSI). NSF/ANSI 49-2002 Class II 
(Laminar Flow) Biosafety Cabinetry [NSF/ 
ANSI 2002]. Addresses classification and 
certification of Class II BSCs and provides 
a definition for Class III BSCs.
■ PDA. Technical Report No. 34: Design 
and Validation of Isolator Systems for 
the Manufacturing and Testing of Health
Care Products [PDA 2001]. A supple­
mental publication to the PDA Journal 
of Pharmaceutical Science and Technol­
ogy. Provides definitions, design, and op­
eration and testing guidance for types of 
isolators used in the health care product 
manufacturing industry.
■ American Glovebox Society (AGS). 
Guidelines for Gloveboxes; 2nd edition 
[AGS 1998]. Provides guidance on the 
design, testing, use, and decommission­
ing of glovebox containment systems.
CASE REPORTS
The following cases illustrate the range of 
health effects reported after exposure to 
antineoplastic drugs:
Case 1
A female oncology nurse was exposed to a 
solution of carmustine when the complete 
tubing system fell out of an infusion bottle 
of carmustine, and all of the solution poured 
down her right arm and leg and onto the 
floor [McDiarmid and Egan 1988]. Although 
she wore gloves, her right forearm was un­
protected, and the solution penetrated her 
clothing and stockings. Feeling no sensation 
on the affected skin areas, she immediately 
washed her arm and leg with soap and water 
but did not change her clothing. A few hours 
later, while at work, she began to experi­
ence minor abdominal distress and profuse 
belching followed by intermittent episodes of 
nonbloody diarrhea with cramping abdomi­
nal pain. Profuse vomiting occurred, after 
which she felt better. The nurse went to the 
emergency room, where her vital signs and 
physical examination were normal. No spe­
cific therapy was prescribed. She felt better 
the following day. Carmustine is known to
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cause gastric upset, and the investigators 
attributed her gastrointestinal distress to 
systemic absorption of carmustine.
Case 2
A 39-year-old pharmacist suffered two epi­
sodes of painless hematuria (blood in the 
urine) and was found to have cancer (a 
grade II papillary transitional cell carcinoma) 
[Levin et al. 1993]. Twelve years before 
her diagnosis, she had worked full time 
for 20 months in a hospital IV preparation 
area where she routinely prepared cyto­
toxic agents, including cyclophosphamide, 
fluorouracil, methotrexate, doxorubicin, and 
cisplatin. She used a horizontal laminar-flow 
hood that directed the airflow toward her. 
Because she was a nonsmoker and had no 
other known occupational or environmental 
risk factors, her cancer was attributed to 
her antineoplastic drug exposure at work— 
though a cause and effect relationship has 
not been established in the literature.
Case 3
A 41-year-old nurse who had worked on an 
oncology ward for 13 years suffered from 
nasal discharge, difficult breathing, and at­
tacks of coughing 1 to 2 hours after begin­
ning work [Walusiak et al. 2002]. During the 
third year of her employment on the ward, 
she developed difficult breathing while away 
from work. Her total IgE was low, and spe­
cific IgE antibodies to common agents and 
skin prick tests to common allergens (in­
cluding latex) were all negative. The patient 
was subjected to a number of single-blind 
bronchial challenge tests with antineoplastic 
drugs, and she was monitored by spirometry 
and peak expiratory flow measurements. On 
the basis of clinical findings, the investiga­
tors concluded that the evidence was con­
sistent with a diagnosis of allergic asthma.
Case 4
A malfunctioning BSC resulted in possible 
exposure of nursing personnel to a number 
of antineoplastic drugs that were prepared 
in the BSC [Kevekordes et al. 1998]. Blood 
samples from the nurses were analyzed 
for genotoxic biomarkers 2 and 9 months 
after replacement of the faulty BSC. At 
2 months, both sister chromatid exchanges 
(SCEs) and micronuclei were significantly 
elevated compared with those of a matched 
control group. At 9 months, the micronu­
clei concentrations were similar to those of 
the 2-month controls. SCEs were not deter­
mined at 9 months. The investigators con­
cluded that the elevation in biomarkers had 
resulted from the malfunctioning of the BSC, 
which resulted in worker exposure to the an­
tineoplastic drugs. They also concluded that 
the subsequent replacement with a new BSC 
contributed to the reduced effect seen with 
the micronucleus test at 9 months.
Case 5
A 41-year-old patient-care assistant work­
ing on an oncology floor developed an 
itchy rash approximately 30 minutes after 
emptying a commode of urine into a toilet 
[Kusnetz and Condon 2003]. She denied 
any direct contact with the urine, wore a 
protective gown and nitrile gloves, and fol­
lowed hospital policy for the disposal of 
materials contaminated with antineoplastic 
drugs. The rash subsided after 1 to 2 days. 
Three weeks later, she had a similar reac­
tion approximately 1 hour after performing 
the same procedure for another patient. 
Upon investigation, it was found that both 
hospital patients had recently been treated 
with vincristine and doxorubicin. The patient- 
care assistant had no other signs or symp­
toms and reported no changes in lifestyle
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and no history of allergies or recent infec­
tions. After treatment with diphenhydramine 
(intramuscular) and oral corticosteroids, her 
symptoms disappeared. Although the cause 
could not be definitely confirmed, both vin­
cristine and doxorubicin have been associ­
ated with allergic reactions when given to 
patients. The aerosolization of the drug pres­
ent in the urine may have provided enough 
exposure for symptoms to develop.
CONCLUSIONS
Recent evidence summarized in this Alert 
documents that worker exposure to hazard­
ous drugs is a persistent problem. Although 
most air-sampling studies have not demon­
strated significant airborne concentrations 
of these drugs, the sampling methods used 
in the past have come into question [Larson 
et al. 2003] and may not be a good indi­
cator of contamination in the workplace. In 
all studies involving examination of surface 
wipe samples, researchers have determined 
that surface contamination of the workplace 
is common and widespread. Also, a number 
of recent studies have documented the ex­
cretion of several indicator drugs in the urine 
of health care workers. Results from studies 
indicate that worker exposure to hazardous 
drugs in health care facilities may result in 
adverse health effects.
Appropriately designed studies have begun 
and are continuing to characterize the ex­
tent and nature of health hazards associated 
with these ongoing exposures. NIOSH is cur­
rently conducting studies to further identify 
potential sources of exposure and methods 
to reduce or eliminate worker exposure to 
these drugs. To minimize these potentially
acute (short-term) and chronic (long-term) 
effects of exposure to hazardous drugs at 
work, NIOSH recommends that at a mini­
mum, employers and health care workers 
follow the recommendations presented in 
this Alert.
RECOMMENDATIONS
Summary of Recommended 
Procedures
1. Assess the hazards in the workplace.
■ Evaluate the workplace to identify and 
assess hazards before anyone begins 
work with hazardous drugs. As part o f 
this evaluation, assess the following:
- Total working environment
- Equipment (i.e., ventilated cabinets, 
closed-system drug transfer devices, 
glovebags, needleless systems, and 
PPE)
- Physical layout of work areas
- Types of drugs being handled
- Volume, frequency, and form of drugs 
handled (tablets, coated versus un­
coated, powder versus liquid)
- Equipment maintenance
- Decontamination and cleaning
- Waste handling
- Potential exposures during work, in­
cluding hazardous drugs, bloodborne 
pathogens, and chemicals used to 
deactivate hazardous drugs or clean 
drug-contaminated surfaces
- Routine operations
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- Spill response
- Waste segregation, containment, and 
disposal
■ Regularly review the current inventory 
o f hazardous drugs, equipment, and 
practices, seeking input from affect­
ed workers. Have the safety and health 
staff or an internal committee perform 
this review.
■ Conduct regular training reviews with 
all potentially exposed workers in work­
places where hazardous drugs are used.
Seek ongoing input from workers who 
handle hazardous drugs and from other 
potentially exposed workers regarding the 
quality and effectiveness of the preven­
tion program. Use this input from workers 
to provide the safest possible equipment 
and conditions for minimizing exposures. 
This approach is the only prudent public 
health approach, since safe concentra­
tions for occupational exposure to haz­
ardous drugs have not been conclusively 
determined.
2. Handle drugs safely.
■ Implement a program for safely han­
dling hazardous drugs at work and 
review this program annually on the 
basis o f the workplace evaluation.
Establish work policies and procedures 
specific to the handling of hazardous 
drugs. These policies and procedures 
should address and define the following:
- Presence of hazardous drugs
- Labeling
- Storage
- Personnel issues (such as exposure 
of pregnant workers)
- Spill control
- Detailed procedures for preparing, 
administering, and disposing of haz­
ardous drugs
■ Establish procedures and provide 
training for handling hazardous drugs 
safely, cleaning up spills, and us­
ing a ll equipment and PPE properly.
Inform workers about the location and 
proper use of spill kits. Make these kits 
available near all potential sources of 
exposure. Make sure that training con­
forms to the requirements of the OSHA 
hazard communication standard [29 
CFR 1910.1200] and other relevant 
OSHA requirements such as the PPE 
standard [29 CFR 1910.132]. In addi­
tion, establish procedures for cleaning 
and decontaminating work areas and 
for proper waste handling and disposal 
of all contaminated materials, including 
patient waste.
■ Establish work practices related to 
both drug manipulation techniques 
and to general hygiene practices— 
such as not permitting eating or drink­
ing in areas where drugs are handled 
(the pharmacy or clinic).
3. Use and maintain equipment 
properly.
■ Develop workplace procedures for 
using and maintaining all equipment 
that functions to reduce exposure— 
such as ventilated cabinets, closed- 
system drug-transfer devices, needle- 
less systems, and PPE.
Detailed Recommendations
Receiving and Storage
■ Begin exposure control when hazardous 
drugs enter the facility. The most sig­
nificant exposure risk during distribution
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and transport is from spills resulting from 
damaged containers.
■ Prepare workers for the possibility that 
spills might occur while they are han­
dling containers (even when packaging 
is intact during routine activities), and 
provide them with appropriate PPE.
■ Make sure that medical products have 
labeling on the outsides of containers 
that will be understood by all workers 
who will be separating hazardous from 
nonhazardous drugs.
■ Wear chemotherapy gloves [ASTM in 
press], protective clothing, and eye 
protection when opening containers 
to unpack hazardous drugs. Such PPE 
protects workers and helps prevent con­
tamination from spreading if damaged 
containers are found.
■ Wear chemotherapy gloves to prevent 
contamination when transporting the vial 
or syringe to the work area.
■ Store hazardous drugs separately from 
other drugs, as recommended by ASHP 
[1990] and other chemical safety stan­
dards.
■ Store and transport hazardous drugs in 
closed containers that minimize the risk 
of breakage.
■ Make sure the storage area has sufficient 
general exhaust ventilation to dilute and 
remove any airborne contaminants.
■ Depending on the physical nature and 
quantity of the stored drugs, consider in­
stalling a dedicated emergency exhaust 
fan that is large enough to quickly purge 
airborne contaminants from the storage 
room in the event of a spill and prevent 
contamination in adjacent areas.
Drug Preparation and Administration
Initial steps
■ As part of the hazard assessment de­
scribed earlier, evaluate and review the 
entire drug preparation and administra­
tion process to identify points at which 
drugs might be released into the work 
environment. Always consider the possi­
bility of contamination on the outside of 
containers [Ros et al. 1997; Hepp and 
Gentschew 1998; Delporte et al. 1999; 
Nygren et al. 2002; Favier et al. 2003; 
Mason et al. 2003].
■ Limit access to areas where drugs are 
prepared to protect persons not involved 
in drug preparation.
■ Coordinate tasks associated with prepar­
ing and administering hazardous drugs 
for most effective control of worker expo­
sures.
Preparing hazardous drugs
■ Use a ventilated cabinet designed to 
reduce worker exposures while preparing 
hazardous drugs (see following section 
entitled Ventilated Cabinets).
■ Train all staff who use ventilated cabinets 
to employ work practices established for 
their particular equipment. The safe use 
of any control depends on proper work.
■ Practice proper technique and use of 
equipment.
■ Include initial and periodic assessments 
of technique in the safety program [Har­
rison et al. 1996], and verify technique 
during drug administration.
■ Wear protective gloves and gowns if you 
are involved in preparation activities 
such as opening drug packaging, han­
dling vials or finished products, labeling
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hazardous drug containers, or disposing 
of waste.
■ Wear PPE (including double gloves and 
protective gowns) while reconstituting 
and admixing drugs:
- Make sure that gloves are labeled 
as chemotherapy gloves and make 
sure such information is available on 
the box [ASTM in press] or from the 
manufacturer.
- Consider latex-sensitive workers 
[NIOSH 1997] and remember that a 
number of glove materials are suit­
able for protecting workers from an­
tineoplastic drugs [Connor 1999; 
Singleton and Connor 1999; Klein et 
al. 2003].
- Consider using chemotherapy gloves 
for hazardous drugs that are not che­
motherapy drugs or for which no in­
formation is available.
- Use double gloving for all activities in­
volving hazardous drugs. Make sure 
that the outer glove extends over 
the cuff of the gown [Connor 1999; 
Brown et al. 2001].
- Inspect gloves for physical defects 
before use.
- Wash hands with soap and water be­
fore donning protective gloves and 
immediately after removal.
- Change gloves every 30 minutes or 
when torn, punctured, or contami­
nated. Discard them immediately in a 
yellow chemotherapy waste container 
[ASHP 1990; Brown et al. 2001].
- Use disposable gowns made of 
polyethylene-coated polypropylene 
(which is nonlinting and nonabsor­
bent). These gowns offer better pro­
tection than polypropylene gowns 
against many of the antineoplastic 
drugs [Connor 1993; Harrison and 
Kloos 1999]. Make sure gowns have 
closed fronts, long sleeves, and elas­
tic or knit closed cuffs.
- Dispose of protective gowns after 
each use.
- Use disposable sleeve covers to pro­
tect the wrist area and remove the 
covers after the task is complete.
■ When drug preparation is complete, seal 
the final product in a plastic bag or other 
sealable container for transport before 
taking it out of the ventilated cabinet.
■ Seal and wipe all waste containers inside 
the ventilated cabinet before removing 
them from the cabinet.
■ Remove all outer gloves and sleeve cov­
ers and bag them for disposal while you 
are inside the ventilated cabinet.
■ Wash hands with soap and water imme­
diately after removing gloves.
■ Consider using devices such as closed- 
system transfer devices, glovebags, and 
needleless systems when transferring 
hazardous drugs from primary packaging 
(such as vials) to dosing equipment (such 
as infusion bags, bottles, or pumps). 
Closed systems limit the potential for gen­
erating aerosols and exposing workers to 
sharps. Evidence documents a decrease in
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drug contaminants inside a Class II BSC 
when a closed-system transfer device 
is used [Sessink et al. 1999; Vandenb- 
roucke and Robays 2001; Connor et al. 
2002; Nygren et al. 2002; Spivey and 
Connor 2003; Wick et al. 2003].
- Remember that a closed-system 
transfer device is not an acceptable 
substitute for a ventilated cabinet 
and should be used only within a 
ventilated cabinet.
- Use appropriate PPE and work prac­
tices even when you are using a 
closed system.
■ Have pharmacy personnel prime the IV 
tubing and syringes inside the ventilated 
cabinet, or prime them in-line with non­
drug solutions—never in the patient’s 
room.
Administering hazardous drugs
■ Administer drugs safely by using protec­
tive medical devices (such as needleless 
and closed systems) and techniques 
(such as priming of IV tubing by phar­
macy personnel inside a ventilated 
cabinet or priming in-line with nondrug 
solutions).
■ Wear PPE (including double gloves, 
goggles, and protective gowns) for all ac­
tivities associated with drug administra­
tion—opening the outer bag, assembling 
the delivery system, delivering the drug 
to the patient, and disposing of all equip­
ment used to administer drugs.
■ Attach drug administration sets to the IV 
bag, and prime them before adding the 
drug to the bag.
■ Never remove tubing from an IV bag con­
taining a hazardous drug.
■ Do not disconnect tubing at other points 
in the system until the tubing has been 
thoroughly flushed.
■ Remove the IV bag and tubing intact 
when possible.
■ Place disposable items directly in a yel­
low chemotherapy waste container and 
close the lid.
■ Remove outer gloves and gowns, and 
bag them for disposal in the yellow che­
motherapy waste container at the site of 
drug administration.
■ Double-bag the chemotherapy waste 
before removing the inner gloves.
■ Consider double bagging all contami­
nated equipment.
■ Wash hands with soap and water before 
leaving the drug administration site.
Ventilated Cabinets
Use of cabinets
■ Mix, prepare, and otherwise manipu­
late, count, crush, compound powders, 
or pour liquid hazardous drugs inside a 
ventilated cabinet designed to prevent 
hazardous drugs from being released 
into the work environment.
■ Do not use supplemental engineering 
or process controls (such as needleless 
systems, glove bags, and closed-system 
drug transfer devices) as a substitution 
for ventilated cabinets, even though 
such controls may reduce the potential 
for exposure when preparing and admin­
istering hazardous drugs.
Selection
■ Consult the following document for per­
formance test methods and selection
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criteria for BSCs: Primary Containment 
for Biohazards: Selection, Installation 
and Use of Biological Safety Cabinets, 
2nd edition [CDC/NIH 2000].
■ Select a ventilated cabinet depending on 
the need for aseptic processing. Aseptic 
technique is important for protecting 
hazardous drugs from possible contami­
nation. However, it is also important to 
consider worker protection and to as­
sure that worker safety and health is 
not sacrificed. Therefore, when asepsis 
is required or recommended, use ven­
tilated cabinets designed for both haz­
ardous drug containment and aseptic 
processing. Aseptic requirements are 
generally regulated by individual State 
boards of pharmacy [Thompson 2003; 
USP 2004].
■ When asepsis is not required, a Class I 
BSC or an isolator intended for contain­
ment applications (a “containment isola­
tor”) may be sufficient.
■ When aseptic technique is required, use 
one of the following ventilated cabinets:
- Class II BSC (Type B2 is preferred, 
but Types A2 and B1 are allowed 
under certain conditions)
- Class III BSC
- Isolators intended for asepsis and 
containment (aseptic containment iso­
lators) [NSF/ANSI 2002; PDA 2001]
Air flow and exhaust
■ Regardless of type, equip each ventilated 
cabinet with a continuous monitoring de­
vice to confirm adequate air flow before 
each use.
■ Use a high-efficiency particulate air filter 
(HEPA filter) for the exhaust from these
controls, and where feasible, exhaust 
100% of the filtered air to the outside.
■ Install the outside exhaust so that the 
exhausted air is not pulled back into the 
building by the heating, ventilating, and 
air conditioning (HVAC) systems or by the 
windows, doors, or other points of entry.
■ Place fans downstream of the HEPA filter 
so that contaminated ducts are main­
tained under negative pressure.
■ Do not use a ventilated cabinet that recir­
culates air inside the cabinet or exhausts 
air back into the room environment un­
less the hazardous drug(s) in use will not 
volatilize (evaporate) while they are be­
ing handled or after they are captured by 
the HEPA filter. Information about vola­
tilization should be supplied by the drug 
manufacturer (possibly in the MSDS) or 
by air-sampling data.
■ Seek additional information about place­
ment of the cabinet, exhaust system, and 
stack design from NSF/ANSI 49-2002 
[NSF/ANSI 2002]. Incorporate their rec­
ommendations regardless of the type of 
ventilated cabinet selected.
Maintenance
■ Identify a safety and health representa­
tive familiar with potential drug expo­
sures and their hazards. Ask that person 
to review in advance all maintenance ac­
tivities performed on ventilated cabinets 
and exhaust systems associated with 
hazardous drug procedures.
■ Develop a written safety plan for all rou­
tine maintenance activities performed on 
equipment that could be contaminated 
with hazardous drugs.
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■ Properly install and maintain and rou­
tinely clean any Class II BSC.
- Field-certify its performance (1) after 
installation, relocation, maintenance 
repairs to internal components, and 
HEPA filter replacement, and (2) ev­
ery 6 months thereafter [NSF/ANSI 
2002; OSHA 1999].
- Prominently display a current field- 
certification label on the ventilated 
cabinet [NSF/ANSI 2002].
■ Treat other types of ventilated cabinets 
similarly with regard to care and fre- 
quency-of-performance verification 
tests.
■ Select the appropriate performance and 
test methods for isolators, depending on 
the type (containment-only or aseptic 
containment), the operating pressure 
(positive or negative and designed mag­
nitude), and the toxicity of the hazardous 
drug:
- At a minimum, provide isolators with 
a leak test and a containment in­
tegrity test such as those described 
in Guidelines for Gloveboxes [AGS 
1998].
- Perform a HEPA filter leak test (de­
scribed in NSF/ANSI [2002]) for iso­
lators that rely on HEPA filtration for 
containment.
- Perform additional tests as required 
by local and/or national jurisdictions 
to verify aseptic conditions.
■ Make sure that workers performing main­
tenance are
- familiar with applicable safety plans,
- warned about hazards, and
- trained in appropriate work tech­
niques and PPE needed to minimize 
exposure.
■ Remove all hazardous drugs and chemi­
cals, and decontaminate the ventilated 
cabinet before beginning maintenance 
activities.
■ Warn occupants in the affected areas 
immediately before the maintenance ac­
tivity begins, and place warning signs on 
all equipment that may be affected.
■ Strictly follow all applicable lockout/tagout 
procedures [29 CFR 1910.147].
■ Decontaminate and bag equipment parts 
removed for replacement or repair before 
they are taken outside the facility.
■ Seal used filtration media in plastic im­
mediately upon removal, and tag it for 
disposal as chemotherapy waste; or dis­
pose of it as otherwise directed by the 
environmental safety and health office or 
applicable regulation.
Routine Cleaning, Decontaminating,
Housekeeping, and Waste Disposal
Cleaning and decontaminating
■ Perform cleaning and decontamination 
work in areas that are sufficiently venti­
lated to prevent buildup of hazardous air­
borne drug concentrations. Develop pro­
tocols prohibiting the use of unventilated 
areas such as storage closets for drug 
storage or any tasks involving hazardous 
drugs.
■ Clean work surfaces with an appropri­
ate deactivation agent (if available) and 
cleaning agent before and after each ac­
tivity and at the end of the work shift.
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■ Establish periodic cleaning routines for 
all work surfaces and equipment that 
may become contaminated, including 
administration carts and trays.
■ At a minimum, wear safety glasses with 
side shields and protective gloves for 
cleaning and decontaminating work.
■ Wear face shields if splashing is possible.
■ Wear protective double gloves for decon­
taminating and cleaning work.
- Select them by referring to the MSDS, 
glove selection guidelines, or informa­
tion from the glove manufacturer.
- Make sure the gloves are chemically 
resistant to the decomtamination or 
cleaning agent used.
Housekeeping
■ Wear two pairs of protective gloves and a 
disposable gown if you must handle lin­
ens, feces, or urine from patients who 
have received hazardous drugs within 
the last 48 hours—or in some cases, 
within the last 7 days [Cass and Mus­
grave 1992].
■ Dispose of the gown after each use or 
whenever it becomes contaminated.
■ Wear face shields if splashing is possible.
■ Remove the outer gloves and the gown 
by turning them inside out and plac­
ing them into the yellow chemotherapy 
waste container. Repeat the procedure 
for the inner gloves.
■ Wash hands with soap and water after 
removing the gloves.
Waste disposal
■ Be aware of the various types of waste 
generated by preparing and administer­
ing hazardous drugs: partially filled vials, 
undispensed products, unused IVs, nee­
dles and syringes, gloves, gowns, under­
pads, and contaminated materials from 
spill cleanups.
■ Place trace wastes (those that contain 
less than 3% by weight of the original 
quantity of hazardous drugs)—such 
as needles, empty vials and syringes, 
gloves, gowns, and tubing—in yellow 
chemotherapy waste containers. As­
suring that drug-contaminated waste is 
properly contained will protect workers 
from respiratory exposure to volatile or 
micro-aerosolized drugs [Connor et al. 
2000; Kiffmeyer et al. 2002; Larson et 
al. 2003].
- Place soft trace items (those that are 
contaminated with trace amounts of 
hazardous drugs) in yellow chemo­
therapy bags for disposal by incin­
eration at a regulated medical waste 
facility.
- Place empty vials and sharps such 
as needles and syringes in chemo­
therapy waste containers designed 
to protect workers from injuries and 
dispose of them by incineration at a 
regulated medical waste facility.
■ Do not place hazardous drug-contami­
nated sharps in red sharps containers 
that are used for infectious wastes, 
since these are often autoclaved or 
microwaved [ASHP 1990; OSHA 1999; 
Smith 2002].
■ Dispose of P-listed arsenic trioxide and 
its containers and any bulk amounts 
of U-listed drugs [40 CFR 261.33] in
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hazardous waste containers at a RCRA- 
permitted incinerator. Nine hazardous 
drugs in Appendix A are listed as hazard­
ous waste5 by EPA.
■ Consider disposing of other bulk hazard­
ous drugs (that is, expired or unused vi­
als, ampoules, syringes, bags, and bot­
tles of hazardous drugs or solutions of 
any other items with more than trace 
contamination) in a manner similar to 
that required for RCRA-defined hazard­
ous wastes as recommended by ASHP
[1990] and OSHA [1999].
Spill Control
■ Manage hazardous drug spills according 
to the established, written policies and 
procedures for each workplace.
■ Be aware that the size of the spill might 
determine who is authorized to conduct 
the cleanup and decontamination and 
how the cleanup is managed.
■ Assure that the written policies and pro­
cedures address the protective equip­
ment required for various spill sizes, the 
possible spreading of material, restricted 
access to hazardous drug spills, and 
signs to be posted.
■ Assure that cleanup of a large spill is 
handled by workers who are trained in 
handling hazardous materials [29 CFR 
1910.120].
■ Locate spill kits and other cleanup mate­
rials in the immediate area where expo­
sures may occur.
§Arsenic trioxide is a P-listed hazardous waste. Chlorambucil, 
cyclophosphamide, daunorubicin HCI, diethylstilbestrol, 
melphalan, mitomycin, streptozocin, and uracil mustard 
are U-listed hazardous wastes. See 40 CFR 261.33.
■ As required by OSHA, follow a complete 
respiratory protection program, including 
fit-testing, if you wear respirators such 
as those contained in some spill kits 
[29 CFR 1910.134]. Use NIOSH-certi- 
fied respirators [42 CFR 84]. Surgical 
masks do not provide adequate pro­
tection.
■ Dispose of all spill cleanup materials in a 
hazardous chemical waste container, in 
accordance with EPA/RCRA regulations 
regarding hazardous waste—not in a 
chemotherapy waste or biohazard con­
tainer.
Medical Surveillance
■ In addition to preventing exposure to haz­
ardous drugs and carefully monitoring the 
environment, make medical surveillance 
an important part of any safe handling 
program for hazardous drugs.
■ If you handle hazardous drugs, partici­
pate in medical surveillance programs 
provided at your workplace.
■ If you handle hazardous drugs but have 
no medical surveillance program at work, 
see your private health care provider for 
routine medical care. Be sure to inform 
him or her about your occupation and 
possible exposures to hazardous drugs.
■ Refer to the OSHA Technical Manual: 
Controlling Occupational Exposure to 
Hazardous Drugs, Section VI Chapter 2 
[OSHA 1999]. This document currently 
recommends that workers handling haz­
ardous drugs be monitored in a medical 
surveillance program that includes the 
taking of a medical and exposure history, 
physical examination, and some labora­
tory tests.
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■ Refer to the guidelines of professional 
organizations such as the ASHP [1990] 
and the Oncology Nursing Society [Brown 
et al. 2001], which recommend medi­
cal surveillance as the recognized stan­
dard of occupational health practice for 
hazardous drug handlers. The American 
College of Occupational and Environ­
mental Medicine (ACOEM) also recom­
mends surveillance for these workers in 
their Reproductive Hazard Management 
Guidelines [ACOEM 1996].
■ Use a worker’s past exposure history as 
a surrogate measure of potential expo­
sure intensity.
■ If you are an occupational health profes­
sional who is examining a drug-exposed 
worker, ask questions that focus on the 
worker’s symptoms relating to the organ 
systems that are known targets for the 
hazardous drugs.
- For example, after an acute expo­
sure such as a splash or other drug 
contact with skin or mucous mem­
branes, focus the physical examina­
tion on the exposed areas and the 
clinical signs of rash or irritation to 
those areas.
- Include a complete blood count with 
differential and a reticulocyte count in 
the baseline and periodic laboratory 
tests. These may be helpful as an 
indicator of bone marrow reserve.
■ Monitor the urine of workers who handle 
hazardous drugs with a urine dipstick or 
a microscopic examination of the urine 
for blood [Brown et al. 2001]. Sev­
eral antineoplastic agents are known to 
cause bladder damage and blood in the 
urine of treated patients.
■ Conduct environmental sampling and/or 
biological monitoring when exposure is 
suspected or symptoms have been noted.
ADDITIONAL INFORMATION
Additional information about exposure to 
hazardous drugs is available at 1-800-35- 
NIOSH (1-800-356-4674), fax: 1-513­
533-8573, E-mail: pubstaft@cdc.gov, or 
Web site: www.cdc.gov/NIOSH.
Additional information about hazardous drug 
safety is available at www.osha.gov.
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APPENDIX A
DRUGS CONSIDERED HAZARDOUS
General Approach to Handling 
Hazardous Drugs
In this Alert, NIOSH presents a standard 
precautions or universal precautions ap­
proach to handling hazardous drugs safely: 
that is, NIOSH recommends that all hazard­
ous drugs be handled as outlined in this 
Alert. Therefore, no attempt has been made 
to perform drug risk assessments or pro­
pose exposure limits. The area of new drug 
development is rapidly evolving as unique 
approaches are being taken to treat cancer 
and other serious diseases.
Defining Hazardous Drugs
Hazardous drugs include those used for 
cancer chemotherapy, antiviral drugs, hor­
mones, some bioengineered drugs, and 
other miscellaneous drugs. The definition of 
hazardous drugs used in this Alert is based 
on an ASHP definition that was originally 
developed in 1990 [ASHP 1990]. Thus the 
definition may not accurately reflect the 
toxicity criteria associated with the newer 
generation of pharmaceuticals entering the 
health care setting. For example, bioen­
gineered drugs target specific sites in the 
body; and although they may or may not be 
toxic to the patient, some may not pose a 
risk to health care workers.
NIOSH and other organizations are still 
gathering data on the potential toxicity and 
health effects related to highly potent drugs 
and bioengineered drugs. Therefore, when 
working with any hazardous drug, health 
care workers should follow a standard pre­
cautions approach along with any recom­
mendations included in the manufacturer’s 
MSDSs.
ASHP Definition of Hazardous 
Drugs
The ASHP defines hazardous drugs in their 
1990 revision of Technical Assistance Bul­
letin on Handling Hazardous Drugs [ASHP 
1990]. The bulletin gives criteria for identify­
ing potentially hazardous drugs that should 
be handled in accordance with an established 
safety program [McDiarmid et al. 1991; Ar­
rington and McDiarmid 1993]. The criteria 
are prioritized to reflect the hierarchy of 
potential toxicity described below. Since the 
hazardous drugs covered by this Alert were 
designed as therapeutic agents for humans, 
human toxicity profiles should be considered 
superior to any data from animal models 
or in vitro systems. Additional guidance for 
defining hazardous drugs is available in the 
following citations: carcinogenicity [61 Fed. 
Reg. 17960-18011 (1996b); IARC 2004], 
teratogenicity [56 Fed. Reg. 63798-63826
(1991)], developmental toxicity [56 Fed. 
Reg. 63798-63826 (1991)], and reproduc­
tive toxicity [61 Fed. Reg. 56274-56322
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(1996a)]. Physical characteristics of the 
agents (such as liquid versus solid, or wa­
ter versus lipid solubility) also need to be 
considered in determining the potential for 
occupational exposure.
NIOSH Revision of ASHP 
Definition
The 1990 ASHP definition of hazardous 
drugs** was revised by the NIOSH Working 
Group on Hazardous Drugs for this Alert. 
Drugs considered hazardous include those 
that exhibit one or more of the following six 
characteristics in humans or animals:
1. Carcinogenicity
2. Teratogenicity or other developmental 
toxicity++
3. Reproductive toxicity++
4. Organ toxicity at low doses++
**ASHP [1990] definition of hazardous drugs:
1. Genotoxicity (i.e., mutagenicity and clastogenicity in 
short-term test systems)
2. Carcinogenicity in animal models, in the patient popula­
tion, or both, as reported by the International Agency for 
Research on Cancer (IARC)
3. Teratogenicity or fertility impairment in animal studies 
or in treated patients
4. Evidence of serious organ or other toxicity at low doses 
in animal models or treated patients.
++All drugs have toxic side effects, but some exhibit toxicity 
at low doses. The level of toxicity reflects a continuum 
from relatively nontoxic to production of toxic effects in 
patients at low doses (for example, a few milligrams or 
less). For example, a daily therapeutic dose of 10 mg/ 
day or a dose of 1 mg/kg per day in laboratory animals 
that produces serious organ toxicity, developmental 
toxicity, or reproductive toxicity has been used by the 
pharmaceutical industry to develop occupational 
exposure limits (OELs) of less than 10 pg/m3 after 
applying appropriate uncertainty factors [Sargent and 
Kirk 1988; Naumann and Sargent 1997; Sargent et 
al. 2002]. OELs in this range are typically established 
for potent or toxic drugs in the pharmaceutical industry. 
Under all circumstances, an evaluation of all available 
data should be conducted to protect health care 
workers.
5. Genotoxicity**
6. Structure and toxicity profiles of new 
drugs that mimic existing drugs de­
termined hazardous by the above 
criteria.
Determining Whether a Drug is 
Hazardous
Many hazardous drugs used to treat cancer 
bind to or damage DNA (for example, alkylat­
ing agents). Other antineoplastic drugs, some 
antivirals, antibiotics, and bioengineered drugs 
interfere with cell growth or proliferation, or 
with DNA synthesis. In some cases, the 
nonselective actions of these drugs disrupt 
the growth and function of both healthy and 
diseased cells, resulting in toxic side effects 
for treated patients. These nonselective 
actions can also cause adverse effects in 
health care workers who are inadvertently 
exposed to hazardous drugs.
Early concerns about occupational expo­
sure to antineoplastic drugs first appeared 
in the 1970s. Although the antineoplastic 
drugs remain the principal focus of this 
Alert, other drugs may also be considered 
hazardous because they are potent (small 
quantities produce a physiological effect) or 
cause irreversible effects. As the use and 
number of these potent drugs increase, so 
do opportunities for hazardous exposures 
among health care workers. For example, 
antineoplastic drugs such as cyclophospha­
mide have immunosuppressant effects that 
proved beneficial for treating nonmalignant
**In evaluating mutagenicity for potentially hazardous drugs, 
responses from multiple test systems are needed before 
precautions can be required for handling such agents. 
The EPA evaluations include the type of cells affected 
and in vitro versus in vivo testing [51 Fed. Reg. 34006­
34012 (1986)].
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diseases such as rheumatoid arthritis 
and multiple sclerosis [Baker et al. 1987; 
Moody et al. 1987; Chabner et al. 1996; 
Abel 2000].
This appendix presents criteria and sources 
of information for determining whether a 
drug is hazardous. When a drug has been 
judged to be hazardous, the various precau­
tions outlined in this Alert should be applied 
when handling that drug. Also included is a 
list of drugs that should be handled as haz­
ardous. This list is based on a compilation of 
lists from four health care facilities and one 
drug manufacturers’ organization.
In addition to using the list of hazardous drugs 
presented here, each organization should 
create its own list of drugs considered to 
be hazardous. This appendix presents guid­
ance for making such a facility-specific list 
(see section entitled How to Generate your 
own List of Hazardous Drugs). Once this list 
is made, newly purchased drugs should be 
evaluated against the organization’s hazard­
ous drug criteria and added to the list if they 
are deemed hazardous.
Some organizations may have inadequate 
resources for determining their own list of 
hazardous drugs. If so, the sample list of 
hazardous drugs in this appendix (current 
only to the printing date of this document) 
will help employers and workers to deter­
mine when precautions are needed. Howev­
er, reliance on such a published list is a con­
cern because it quickly becomes outdated 
as new drugs continually enter the market 
or listed drugs are removed when additional 
information becomes available. To fill this 
knowledge gap, NIOSH will update an inter­
net list annually, adding new drugs consid­
ered to be hazardous and removing those
that require reclassification. This hazardous 
drug list will be posted on the NIOSH Web 
site at www.cdc.gov/niosh.
How to Generate Your Own List of 
Hazardous Drugs
The OSHA hazard communication standard 
[29 CFR 1910.1200] requires employers to 
develop a hazard communication program 
appropriate for their unique workplace. An 
essential part of the program is the identifi­
cation of all hazardous drugs a worker may 
encounter in the facility. Compliance with 
the OSHA hazard communication standard 
entails (1) evaluating whether these drugs 
meet one or more of the criteria for defining 
hazardous drugs and (2) posting a list of the 
hazardous drugs to ensure worker safety. 
Institutions may wish to compare their lists 
to the sample listing in this document or on 
the NIOSH Web site.
It is not likely that every health care pro­
vider or facility will use all drugs that have 
received U.S. Food and Drug Administra­
tion (FDA) approval, and the OSHA hazard 
communication standard does not mandate 
evaluation of every marketed drug. Instead, 
compliance requires practice-specific as­
sessments for drugs used at any one time 
by a facility. However, hazardous drug evalu­
ation is a continual process. Local hazard 
communication programs should provide 
for assessment of new drugs as they en­
ter the marketplace, and when appropriate, 
reassessment of their presence on haz­
ardous drug lists as toxicological data be­
come available to support recategorization. 
Toxicological data are often incomplete or 
unavailable for investigational drugs. How­
ever, if the mechanism of action suggests 
that there may be a concern, it is prudent
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to handle them as hazardous drugs until 
adequate information becomes available to 
exclude them.
Some drugs defined as hazardous may not 
pose a significant risk of direct occupational 
exposure because of their dosage formula­
tion (for example, coated tablets or cap- 
sules—solid, intact medications that are ad­
ministered to patients without modifying the 
formulation). However, they may pose a risk 
if solid drug formulations are altered, such as 
by crushing tablets or making solutions from 
them outside a ventilated cabinet.
Where to Find Information 
Related to Drug Toxicity
Practice-specific lists of hazardous drugs 
(usually developed by pharmacy or nursing 
departments) should be comprehensive, in­
cluding all hazardous medications routinely 
used or very likely to be used by a local prac­
tice. Some of the resources that employers 
can use to evaluate the hazard potential of 
a drug include, but are not limited to, the 
following:
■ MSDSs
■ Product labeling approved by the U.S. 
FDA (package inserts)
■ Special health warnings from drug man­
ufacturers, FDA, and other professional 
groups and organizations
■ Reports and case studies published in 
medical and other health care profession 
journals
■ Evidence-based recommendations from 
other facilities that meet the criteria de­
fining hazardous drugs
Examples of Hazardous Drugs
The following list contains a sampling of ma­
jor hazardous drugs. The list was compiled 
from information provided by (1) four insti­
tutions that have generated lists of hazard­
ous drugs for their respective facilities, (2) 
the American Hospital Formulary Service 
Drug Information (AHFS DI) monographs 
[ASHP/AHFS DI 2003], and (3) several other 
sources. The OSHA hazard communication 
standard requires hazardous drugs to be 
handled using special precautions. The man­
date applies not only to health care profes­
sionals who provide direct patient care but 
also to others who support patient care by 
participating in product acquisition, storage, 
transportation, housekeeping, and waste dis­
posal. Institutions may want to adopt this list 
or compare theirs with the list on the NIOSH 
Web site.
Caution: Drugs purchased and used by a 
facility may have entered the marketplace 
after the list below was assembled. There­
fore, this list may not be all-inclusive.
If you use a drug that is not included in the 
list of examples, check the available litera­
ture to see whether the unlisted drug should 
be treated as hazardous. Check the MSDS 
or the proper handling section of the pack­
age insert; or check with other institutions 
that might be using the same drug. If any 
of the documents mention carcinogenicity, 
genotoxicity, teratogenicity, or reproductive or 
developmental toxicity, use the precautions 
stipulated in this Alert. If a drug meets one or 
more of the criteria for hazardous drugs listed 
in this Alert, handle it as hazardous.
The listing below is a sample of what will be 
available on the NIOSH Web site [www.cdc.gov/ 
niosh], and this list will be updated annually.
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Aldesleukin 4,5 10:00 Antineoplastic agents
Alemtuzumab 1,3,4,5 10:00 Antineoplastic agents
Alitretinoin 3,4 ,5 84 :36  Miscellaneous skin and 
mucous membrane agents (Retinoid)
Altretamine 1,2,3,4,5 Not in AHFS (Antineoplastic agent)
Amsacrine 3,5 Not in AHFS (Antineoplastic agent)
Anastrozole 1,5 10:00 Antineoplastic agents
Arsenic trioxide 1,2,3,4,5 10:00 Antineoplastic agents
Asparaginase 1,2,3,4,5 10:00 Antineoplastic agents
Azacitidine 3,5 Not in AHFS (antineoplastic agent)
Azathioprine 2,3,5 92:00  Unclassified therapeutic 
agents (immunosuppressant)
Bacillus Calmette-Guerin 1,2,4 80:12 Vaccines
Bexarotene 2,3,4 ,5 10:00 Antineoplastic agents
Bicalutamide 1,5 10:00 Antineoplastic agents
Bleomycin 1,2,3,4,5 10:00 Antineoplastic agents
Busulfan 1,2,3,4,5 10:00 Antineoplastic agents
Capecitabine 1,2,3,4,5 10:00 Antineoplastic agents
Carboplatin 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Carmustine 1,2,3,4,5 10:00 Antineoplastic agents
Cetrorelix acetate 5 92:00  Unclassified therapeutic 
agents (GnRH antagonist)
Chlorambucil 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Chloramphenicol 1,5 8:12 Antibiotics
Choriogonadotropin alfa 5 68:18 Gonadotropins
Cidofovir 3,5 8 :18  Antivirals
Cisplatin 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Cladribine 1,2,3,4,5 10:00 Antineoplastic agents
Colchicine 5 92:00  Unclassified therapeutic 
agents (mitotic inhibitor)
(See footnotes at end of table)
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Sample list of drugs that should be handled as hazardous* (Continued)
AHFS Pharmacologic-Therapeutic 
Drug Source Classification
Cyclophosphamide 1,2,3,4,5 10:00 Antineoplastic agents
Cytarabine 1,2,3,4,5 10:00 Antineoplastic agents
Cyclosporin 1 92:00  Immunosuppressive agents
Dacarbazine 1,2,3,4,5 10:00 Antineoplastic agents
Dactinomycin 1,2,3,4,5 10:00 Antineoplastic agents
Daunorubicin HCl 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Denileukin 3,4 ,5 10:00 Antineoplastic agents
Dienestrol 5 68:16.04  Estrogens
Diethylstilbestrol 5 Not in AHFS (nonsteroidal synthetic 
estrogen)
Dinoprostone 5 76:00 Oxytocics
Docetaxel 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Doxorubicin 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Dutasteride 5 92:00  Unclassified therapeutic 
agents (5-alpha reductase inhibitor)
Epirubicin 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Ergonovine/methylergonovine 5 76:00 Oxytocics
Estradiol 1,5 68:16.04  Estrogens
Estramustine phosphate 
sodium




Estrogens, conjugated 5 68:16.04  Estrogens
Estrogens, esterified 5 68:16.04  Estrogens
Estrone 5 68:16.04  Estrogens
Estropipate 5 68:16.04  Estrogens
Etoposide 1,2,3,4,5 10:00 Antineoplastic agents
Exemestane 1,5 10:00 Antineoplastic agents
Finasteride 1,3,5 92:00  Unclassified therapeutic 
Agents (5-alpha reductase inhibitor)
Floxuridine 1,2,3,4,5 10:00 Antineoplastic agents
(See footnotes at end of ta
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Fludarabine 1,2,3,4,5 10:00 Antineoplastic agents
Fluorouracil 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Fluoxymesterone 5 68:08 Androgens
Flutamide 1,2,5 10:00 Antineoplastic agents
Fulvestrant 5 10:00 Antineoplastic agents
Ganciclovir 1 ,2 ,3,4,5 8 :18  Antiviral
Ganirelix acetate 5 92:00  Unclassified therapeutic 
agents (GnRH antagonist)
Gemcitabine 1,2,3,4,5 10:00 Antineoplastic agents
Gemtuzumab ozogamicin 1,3,4,5 10:00 Antineoplastic agents
Gonadotropin, chorionic 5 68:18 Gonadotropins
Goserelin 1,2,5 10:00 Antineoplastic agents
Hydroxyurea 1,2,3,4,5 10:00 Antineoplastic agents
Ibritumomab tiuxetan 3 10:00 Antineoplastic agents
Idarubicin 1 ,2 ,3,4,5 Not in AHFS (antineoplastic agent)
Ifosfamide 1,2,3,4,5 10:00 Antineoplastic agents
Imatinib mesylate 1,3,4,5 10:00 Antineoplastic agents
Interferon alfa-2a 1,2,4,5 10:00 Antineoplastic agents
Interferon alfa-2b 1,2,4,5 10:00 Antineoplastic agents
Interferon alfa-n1 1,5 10:00 Antineoplastic agents
Interferon alfa-n3 1,5 10:00 Antineoplastic agents
Irinotecan HCl 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Leflunomide 3,5 92:00  Unclassified therapeutic agents 
(antineoplastic agent)
Letrozole 1,5 10:00 Antineoplastic agents
Leuprolide acetate 1,2,5 10:00 Antineoplastic agents
Lomustine 1,2,3,4,5 10:00 Antineoplastic agents
Mechlorethamine 1,2,3,4,5 10:00 Antineoplastic agents
Megestrol 1,5 10:00 Antineoplastic agents
Melphalan 1,2,3,4,5 10:00 Antineoplastic agents
(See footnotes at end of table)
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Menotropins 5 68:18 Gonadotropins
Mercaptopurine 1,2,3,4,5 10:00 Antineoplastic agents
Methotrexate 1,2,3,4,5 10:00 Antineoplastic agents
Methyltestosterone 5 68:08 Androgens
Mifepristone 5 76:00 Oxytocics
Mitomycin 1,2,3,4,5 10:00 Antineoplastic agents
Mitotane 1,4,5 10:00 Antineoplastic agents
Mitoxantrone HCl i,2 ,3 ,4 ,5 10:00 Antineoplastic agents
Mycophenolate mofetil 1,3,5 92:00  Immunosuppressive agents
Nafarelin 5 68:18 Gonadotropins
Nilutamide 1,5 10:00 Antineoplastic agents
Oxaliplatin 1,3,4,5 10:00 Antineoplastic agents
Oxytocin 5 76:00 Oxytocics
Paclitaxel 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Pegaspargase 1,2,3,4,5 10:00 Antineoplastic agents
Pentamidine isethionate 1,2,3,5 8 :40  Miscellaneous anti-infectives
Pentostatin 1 ,2 ,3,4,5 10:00 Antineoplastic agents
Perphosphamide 3,5 Not in AHFS (antineoplastic agent)
Pipobroman 3,5 Not in AHFS (antineoplastic agent)
Piritrexim isethionate 3,5 Not in AHFS (antineoplastic agent)
Plicamycin 1,2,3,5 Not in AHFS (antineoplastic agent)
Podoflilox 5 84:36  Miscellaneous skin and mucous 
membrane agents (mitotic inhibitor)
Podophyllum resin 5 84:36  Miscellaneous skin and mucous 
membrane agents (mitotic inhibitor)
Prednimustine 3,5 Not in AHFS (antineoplastic agent)
Procarbazine 1,2,3,4,5 10:00 Antineoplastic agents
Progesterone 5 68:32 Progestins
Progestins 5 68:12 Contraceptives
(See footnotes at end of table)
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Raloxifene 5 68:16.12 Estrogen agonists-antago- 
nists
Raltitrexed 5 Not in AHFS (antineoplastic agent)
Ribavirin 1,2,5 8 :18  Antiviral
Streptozocin 1,2,3,4,5 10:00 Antineoplastic agents
Tacrolimus 1,5 92:00  Unclassified therapeutic 
agents (immunosuppressant)
Tamoxifen 1,2,5 10:00 Antineoplastic agents
Temozolomide 3,4 ,5 10:00 Antineoplastic agents
Teniposide 1,2,3,4,5 10:00 Antineoplastic agents
Testolactone 5 10:00 Antineoplastic agents
Testosterone 5 68:08 Androgens
Thalidomide 1,3,5 92:00  Unclassified therapeutic 
agents (immunomodulator)
Thioguanine 1,2,3,4,5 10:00 Antineoplastic agents
Thiotepa 1,2,3,4,5 10:00 Antineoplastic agents
Topotecan 1,2,3,4,5 10:00 Antineoplastic agents
Toremifene citrate 1,5 10:00 Antineoplastic agents
Tositumomab 3,5 Not in AHFS (antineoplastic agent)
Tretinoin 1,2,3,5 84 :16  Cell stimulants and 
proliferants (retinoid)
Trifluridine 1,2,5 52 :04 .06  antivirals
Trimetrexate glucuronate 5 8 :40  Miscellaneous anti-infectives 
(folate antagonist)
Triptorelin 5 10:00 Antineoplastic agents
Uracil mustard 3,5 Not in AHFS (antineoplastic agent)
Valganciclovir 1,3,5 8 :18  Antiviral
Valrubicin 1,2,3,5 10:00 Antineoplastic agents
Vidarabine 1,2,5 52 :04 .06  Antivirals
Vinblastine sulfate 1 ,2 ,3,4,5 10:00 Antineoplastic agents
(See footnotes at end of table)
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Vincristine sulfate i,2 ,3 ,4 ,5 10:00 Antineoplastic agents
Vindesine 1,5 Not in AHFS (antineoplastic agent)
Vinorelbine tartrate 1,2 ,3,4,5 10:00 Antineoplastic agents
Zidovudine 1,2,5 8 :18 :08  Antiretroviral agents
*These lists of hazardous drugs were used with the permission of the institutions that provided them and were adapted for 
use by NIOSH. The sample lists are intended to guide health care providers in diverse practice settings and should not 
be construed as complete representations of all of the hazardous drugs used at the referenced institutions. Some drugs 
defined as hazardous may not pose a significant risk of direct occupational exposure because of their dosage formulation 
(for example, intact medications such as coated tablets or capsules that are administered to patients without modifying 
the formulation). However, they may pose a risk if solid drug formulations are altered outside a ventilated cabinet (for 
example, if tablets are crushed or dissolved, or if capsules are pierced or opened).
1The NIH Clinical Center, Bethesda, MD (Revised 8/2002).
The NIH Health Clinical Center Hazardous Drug (HD) List is part of the NIH Clinical Center’s hazard communication 
program. It was developed in compliance with the OSHA hazard communication standard [29 CFR 1910.1200] as it 
applies to hazardous drugs used in the workplace. The list is continually revised and represents the diversity of medical 
practice at the NIH Clinical Center; however, its content does not reflect an exhaustive review of all FDA-approved 
medications that may be considered hazardous, and it is not intended for use outside the NIH.
2The Johns Hopkins Hospital, Baltimore, MD (Revised 9/2002).
3The Northside Hospital, Atlanta, GA (Revised 8/2002).
4The University of Michigan Hospitals and Health Centers, Ann Arbor, MI (Revised 2/2003).
5This sample listing of hazardous drugs was compiled by the Pharmaceutical Research and Manufacturers of America 
(PhRMA) using information from the AHFS DI monographs published by ASHP in selected AHFS Pharmacologic- 
Therapeutic Classification categories [ASHP/AHFS DI 2003] and applying the definition for hazardous drugs. The list also 
includes drugs from other sources that satisfy the definition for hazardous drugs [PDR 2004; Sweetman 2002; Shepard 
2001; Schardein 2000; REPROTOX 2003]. Newly approved drugs that have structures or toxicological profiles that mimic 
the drugs on this list should also be included. This list was revised in June 2004.
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APPENDIX B
ABBREVIATIONS AND GLOSSARY
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
AHFS American Hospital Formulary Service
AHFS DI American Hospital Formulary Service Drug Information
AGS American Glovebox Society
ANSI American National Standards Institute
ASHP American Society of Health-System Pharmacists (before 1995,
American Society of Hospital Pharmacists)
BSC Biological safety cabinet
CDC Centers for Disease Control and Prevention
FDA U.S. Food and Drug Administration
ft foot (feet)
HEPA high-efficiency particulate air
HIV human immunodeficiency virus
HVAC heating, ventilating, and air conditioning
IARC International Agency for Research on Cancer
IV intravenous
kg kilogram(s)




MSDS material safety data sheet
NIH National Institutes of Health
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NIOSH National Institute for Occupational Safety and Health
NSF National Sanitation Foundation
OEL(s) occupational exposure limit(s)
ONS Oncology Nursing Society
OSHA Occupational Safety and Health Administration
PDA PDA (formerly, the Parenteral Drug Association)
PEL(s) permissible exposure limit(s)
PPE personal protective equipment
RCRA Resource Conservation and Recovery Act
REL(s) recommended exposure limit(s)
RN registered nurse
SCE(s) sister chromatid exchange(s)
TLVs® threshold limit values of the ACGIH
jug microgram
WEEL workplace environmental exposure limit
Glossary
Antineoplastic drug: A chemotherapeu­
tic agent that controls or kills cancer cells. 
Drugs used in the treatment of cancer are 
cytotoxic but are generally more damaging 
to dividing cells than to resting cells.
Aseptic: Free of living pathogenic organ­
isms or infected materials.
Barrier system: An open system that can 
exchange unfiltered air and contaminants 
with the surrounding environment.
Barrier isolator: This term has various in­
terpretations, especially as they pertain to 
hazard containment and aseptic process­
ing. For this reason, it has been omitted 
from this Alert.
Biohazard: An infectious agent or hazard­
ous biological material that presents a risk 
to the health of humans or the environment. 
Biohazards include tissue, blood or body flu­
ids, and materials such as needles or other 
equipment contaminated with these infec­
tious agents or hazardous biological materi­
als.
Biomarker: A biological, biochemical or 
structural change that serves as an indica­
tor of potential damage to cellular compo­
nents, whole cells, tissues, or organs.
BSC (biological safety cabinet): A BSC
may be one of several types, as described 
here [CDC/NIH 1999; NSF/ANSI 2002]:
Class I BSC: A BSC that protects per­
sonnel and the work environment but 
does not protect the product. It is a
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negative-pressure, ventilated cabinet usu­
ally operated with an open front and a 
minimum face velocity at the work open­
ing of at least 75 ft/min. A Class I BSC is 
similar in design to chemical fume hood 
except all of the air from the cabinet is 
exhausted through a HEPA filter (either 
into the laboratory or to the outside).
Class II BSC: A ventilated BSC that 
protects personnel, product, and the 
work environment. A Class II BSC has 
an open front with inward airflow for per­
sonnel protection, downward HEPA-fil- 
tered laminar airflow for product protec­
tion, and HEPA-filtered exhausted air for 
environmental protection.
Type A1 (formerly, Type A): These 
Class II BSCs maintain a minimum in­
flow velocity of 75 ft/min, have HEPA- 
filtered downflow air that is a portion 
of the mixed downflow and inflow air 
from a common plenum, may exhaust 
HEPA-filtered air back into the labora­
tory or to the environment through an 
exhaust canopy, and may have posi­
tive-pressure contaminated ducts and 
plenums that are not surrounded by 
negative-pressure plenums. They are 
not suitable for use with volatile toxic 
chemicals and volatile radionucleo­
tides.
Type A2 (formerly, Type B3): These 
Class II BSCs maintain a minimum 
inflow velocity of 100 ft/min, have 
HEPA-filtered downflow air that is a 
portion of the mixed downflow and 
inflow air from a common exhaust 
plenum, may exhaust HEPA-filtered 
air back into the laboratory or to the 
environment through an exhaust 
canopy, and have all contaminated
ducts and plenums under negative- 
pressure or surrounded by negative- 
pressure ducts and plenums. If these 
cabinets are used for minute quanti­
ties of volatile toxic chemicals and 
trace amounts of radionucleotides, 
they must be exhausted through 
properly functioning exhaust cano­
pies.
Type B1: These Class II BSCs main­
tain a minimum inflow velocity of 100 
ft/min, have HEPA-filtered downflow 
air composed largely of uncontami­
nated, recirculated inflow air, exhaust 
most of the contaminated downflow 
air through a dedicated duct exhaust­
ed to the atmosphere after passing 
it through a HEPA filter, and have all 
contaminated ducts and plenums un­
der negative pressure or surrounded 
by negative-pressure ducts and ple­
nums. If these cabinets are used 
for work involving minute quantities 
of volatile toxic chemicals and trace 
amounts of radionucleotides, the 
work must be done in the directly ex­
hausted portion of the cabinet.
Type B2 (total exhaust): These Class 
II BSCs maintain a minimum inflow ve­
locity of 100 ft/min, have HEPA-filtered 
downflow air drawn from the laboratory 
or the outside, exhaust all inflow and 
downflow air to the atmosphere after 
filtration through a HEPA filter with­
out recirculation inside the cabinet or 
return to the laboratory, and have all 
contaminated ducts and plenums un­
der negative pressure or surrounded by 
directly exhausted negative-pressure 
ducts and plenums. These cabinets 
may be used with volatile toxic chemi­
cals and radionucleotides.
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Class III BSC: A BSC with a totally en­
closed, ventilated cabinet of gas-tight 
construction in which operations are con­
ducted through attached rubber gloves 
and observed through a nonopening view 
window. This BSC is maintained under 
negative pressure of at least 0.50 inch 
of water gauge, and air is drawn into the 
cabinet through HEPA filters. The exhaust 
air is treated by double HEPA filtration or 
single HEPA filtration/incineration. Pas­
sage of materials in and out of the cabi­
net is generally performed through a dunk 
tank (accessible through the cabinet floor) 
or a double-door pass-through box (such 
as an autoclave) that can be decontami­
nated between uses. For a more detailed 
description, refer to CDC/NIH [2000], 
Primary Containment for Biohazards: Se­
lection, Installation and Use of Biological 
Safety Cabinets, 2nd edition. [www.cdc. 
gov/od/ohs/biosfty/bsc/bsc.htm].
Chemotherapy drug: A chemical agent 
used to treat diseases. The term usually 
refers to a drug used to treat cancer.
Chemotherapy glove: A medical glove that 
has been approved by the FDA for use when 
handling antineoplastic drugs.
Chemotherapy waste: Discarded items such 
as gowns, gloves, masks, IV tubing, empty 
bags, empty drug vials, needles and syringes, 
and other items generated while preparing 
and administering antineoplastic agents.
Closed system: A device that does not ex­
change unfiltered air or contaminants with 
the adjacent environment.
Closed system drug-transfer device: A drug 
transfer device that mechanically prohibits the 
transfer of environmental contaminants into
the system and the escape of hazardous 
drug or vapor concentrations outside the 
system.
Cytotoxic: A pharmacologic compound that 
is detrimental or destructive to cells within 
the body.
Deactivation: Treating a chemical agent (such 
as a hazardous drug) with another chemical, 
heat, ultraviolet light, or other agent to create 
a less hazardous agent.
Decontamination: Inactivation, neutraliza­
tion, or removal of toxic agents, usually by 
chemical means.
Engineering controls: Devices designed 
to eliminate or reduce worker exposures to 
chemical, biological, radiological, ergonomic, 
or physical hazards. Examples include labo­
ratory fume hoods, glove bags, retracting sy­
ringe needles, sound-dampening materials 
to reduce noise levels, safety interlocks, and 
radiation shielding.
Genotoxic: Capable of damaging the DNA 
and leading to mutations.
Glove box: A controlled environment work 
enclosure providing a primary barrier from 
the work area. Operations are performed 
through sealed gloved openings to protect 
the worker, the ambient environment, and/ 
or the product.
Glove bag: A glove box made from a flex­
ible plastic film. Operations are performed 
through sealed gloved openings to protect 
the worker, the work environment, and/or 
the product.
Hazardous drug: Any drug identified by at 
least one of the following six criteria: carci­
nogenicity, teratogenicity or developmental
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toxicity, reproductive toxicity in humans, or­
gan toxicity at low doses in humans or ani­
mals, genotoxicity, or new drugs that mimic 
existing hazardous drugs in structure or tox­
icity.
Hazardous waste: Any waste that is a 
RCRA-listed hazardous waste [40 CFR 
261.30-33] or that meets a RCRA charac­
teristic of ignitability, corrosivity, reactivity, or 
toxicity as defined in 40 CFR 261.21-24.
Health care settings: All hospitals, medi­
cal clinics, outpatient facilities, physicians’ 
offices, retail pharmacies, and similar facili­
ties dedicated to the care of patients.
Health care worker: All workers who are 
involved in the care of patients. These in­
clude pharmacists, pharmacy technicians, 
nurses (registered nurses [RNs], licensed 
practical nurses [LPNs], nurses aids, etc.), 
physicians, home health care workers and 
environmental services workers (house­
keeping, laundry, and waste disposal).
HEPA filter: High-efficiency particulate air 
filter rated 99.97% efficient in capturing 
0.3-micron-diameter particles.
Horizontal laminar flow hood (horizontal 
laminar flow clean bench): A device that 
protects the work product and the work area 
by supplying HEPA-filtered air to the rear of 
the cabinet and producing a horizontal flow 
across the work area and out toward the 
worker.
Isolator: A device that is sealed or is sup­
plied with air through a microbially retentive 
filtration system (HEPA minimum) and may 
be reproducibly decontaminated. When 
closed, an isolator uses only decontami­
nated interfaces (when necessary) or rapid
transfer ports (RTPs) for materials transfer. 
When open, it allows for the ingress and/or 
egress of materials through defined open­
ings that have been designed and validated 
to preclude the transfer of contaminants or 
unfiltered air to adjacent environments. An 
isolator can be used for aseptic processing, 
for containment of potent compounds, or 
for simultaneous asepsis and containment. 
Some isolator designs allow operations 
within the isolator to be conducted through 
attached rubber gloves without compromis­
ing asepsis and/or containment.
Aseptic isolator: A ventilated isolator 
designed to exclude external contamina­
tion from entering the critical zone inside 
the isolator.
Aseptic containment isolator: A ven­
tilated isolator designed to meet the 
requirements of both an aseptic isolator 
and a containment isolator.
Containment isolator: A ventilated iso­
lator designed to prevent the toxic ma­
terials processed inside it from escaping 
to the surrounding environment.
Lab coat: A disposable or reusable open- 
front coat, usually made of cloth or other 
permeable material.
MSDS: Material safety data sheet. These 
sheets contain summaries provided by the 
manufacturer to describe the chemical prop­
erties and hazards of specific chemicals and 
ways in which workers can protect them­
selves from exposure to these chemicals.
Mutagenic: Capable of increasing the spon­
taneous mutation rate by causing changes in 
the DNA.
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OEL: Occupational exposure limit. An indus­
try or other nongovernment exposure limit 
usually based on scientific calculations of 
airborne concentrations of a substance that 
are considered to be acceptable for healthy 
workers.
PDA: An international trade association 
serving pharmaceutical science and tech­
nology. Formerly known as the Parenteral 
Drug Association.
PEL: OSHA permissible exposure limit: The 
time-weighted average concentration of a 
substance to which nearly all workers may 
be exposed for up to 8 hours per day, 40 
hours per week for 30 years without adverse 
effects. A PEL may also include a skin des­
ignation.
PPE: Personal protective equipment. Items 
such as gloves, gowns, respirators, goggles, 
face shields, and others that protect indi­
vidual workers from hazardous physical or 
chemical exposures.
REL: NIOSH recommended exposure limit: 
An occupational exposure limit recommend­
ed by NIOSH as being protective of worker 
health and safety over a working lifetime. 
The REL is frequently expressed as a time- 
weighted average exposure to a substance 
for up to a 10-hour workday during a 40- 
hour work week.
Respirator: A type of PPE that prevents 
harmful materials from entering the respi­
ratory system, usually by filtering hazardous 
agents from workplace air. A surgical mask 
does not offer respiratory protection.
Risk assessment: Characterization of po­
tentially adverse health effects from human 
exposure to environmental or occupational 
hazards. Risk assessment can be divided
into five major steps: hazard identification, 
dose-response assessment, exposure as­
sessment, risk characterization, and risk 
communication.
Sister chromatid exchange: The exchange 
of segments of DNA between sister chroma­
tids.
Standard precautions (formerly univer­
sal precautions): The practice in health 
care of treating all patients as if they were 
infected with HIV or other similar diseases 
by using barriers to avoid known means of 
transmitting infectious agents [CDC 1987, 
1988]. These barriers can include nonporous 
gloves, goggles, and face shields. Careful 
handling and disposal of sharps or the use 
of needleless systems are also important.
TLVs®: Threshold limit values. These values 
are exposure limits established by the AC- 
GIH. They refer to airborne concentrations 
of chemical substances and represent con­
ditions under which it is believed that nearly 
all workers may be repeatedly exposed, day 
after day, over a working lifetime, without 
adverse health effects.
Ventilated cabinet: A type of engineering 
control designed for purposes of worker pro­
tection (as used in this document). These 
devices are designed to minimize worker ex­
posures by controlling emissions of airborne 
contaminants through the following:
■ The full or partial enclosure of a potential 
contaminant source
■ The use of airflow capture velocities to 
capture and remove airborne contami­
nants near their point of generation
■ The use of air pressure relationships that 
define the direction of airflow into the 
cabinet
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Examples of ventilated cabinets include 
BSCs, containment isolators, and laboratory 
fume hoods.
WEEL (workplace environmental expo­
sure level): Occupational exposure limits
developed by the American Industrial Hy­
giene Association as a chemical concen­
tration to which nearly all workers may be 
repeatedly exposed for a working lifetime 
without adverse health effects.
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APPENDIX C
NIOSH HAZARDOUS DRUG SAFETY WORKING GROUP
The following members of the NIOSH Haz­
ardous Drug Safety Working Group provided 
leadership, information, and recommenda­
tions for this document:
Tito Aldape, Microflex Corporation
Roger W. Anderson, Dr.RH., University of 
Texas M.D. Anderson Cancer Center
Britton Berek, Joint Commission on 
Accreditation of Healthcare Organizations
Stephen Brightwell, NIOSH
G. Edward Burroughs, Rh.D., C.I.H., NIOSH
Thomas H. Connor, Rh.D., NIOSH
Barbara D. Coyle, B.S.N., R.N. C.O.H.N.-S., 
State of Wisconsin
Gayle DeBord, Rh.D., NIOSH
Robert DeChristoforo, M.S., National 
Institutes of Health
Rhillup C. Dugger, U.S. Oncology, Inc.
Barbara A. Grajewski, Rh.D., NIOSH
Dori Greene, U.S. Oncology, Inc.
Duane R. Hammond, B.S.M.E., NIOSH
Bruce R. Harrison, M.S., R.Rh., B.C.O.R, 
Department of Veterans Affairs
Hye-Joo Kim, U.S. Food and Drug 
Administration
L.D. King, International Academy of 
Compounding Rharmacists
Nancy Kramer, R.N., B.S.N., Coram 
Healthcare
R. David Lauper, Pharm.D., SuperGen, Inc.
Melissa M. Leone, R.N., B.S.N., Apria 
Healthcare
Chiu S. Lin, Ph.D., U.S. Food and Drug 
Administration
Barbara A. MacKenzie, NIOSH
Charlene Maloney, NIOSH
Melissa A. McDiarmid, M.D., M.PH., 
University of Maryland
Kenneth M. Mead, M.S., PE., NIOSH
Martha T. O’Lone, U.S. Food and Drug 
Administration
Jerry Phillips, U.S. Food and Drug 
Administration
Marty Polovich, M.N., R.N., A.O.C.N., 
Oncology Nursing Society
Luci Power, M.S., R.Ph., University of 
California Medical Center
Angela C. Presson, M.D., M.PH., OSHA
Hank Rahe, Containment Technologies 
Group, Inc
Laurence D. Reed, M.S., NIOSH
Anita L. Schill, Ph.D., M.PH., NIOSH
Teresa Schnorr, Ph.D., NIOSH
Douglas Sharpnack, D.V.M., NIOSH
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Charlotte A. Smith, M.S., R.Ph., 
PharmEcology Associates, LLC
Sandi Yurichuk, American Federation of 
State, County and Municipal Employees
American Nurses Association
American Society of Health-System 
Pharmacists
Oncology Nursing Society
Pharmaceutical Research and 
Manufacturers of America
Service Employees International Union
U.S. Environmental Protection Agency
Baxa Corporation
Nuaire, Inc
The Baker Company, Inc.
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